成人霍奇金淋巴瘤69例临床预后分析

doi:10.3969/j.issn.1004-583X.2016.01.015

临床荟萃 ›› 2016, Vol. 31 ›› Issue (1): 59-62.doi: 10.3969/j.issn.1004-583X.2016.01.015

成人霍奇金淋巴瘤69例临床预后分析

赵卫华¹, 徐海萍², 彭志刚¹, 姚奕斌¹, 姜彦枫¹, 马劼¹

1. 广西医科大学第一附属医院血液科, 广西南宁 530021;
2. 北海市人民医院血液科,广西北海 536000

收稿日期:2015-09-15 出版日期:2016-01-05 发布日期:2016-04-19
通讯作者: 马劼,Email:majie086@163.com
基金资助:
广西自然科学基金资助项目(2011GXNSFA018256); 广西医疗卫生适宜技术研究与开发项目(s201303-04)

Clinical prognostic analysis on 69 cases of adult Hodgkin lymphoma

Zhao Weihua¹, Xu Haiping², Peng Zhigang¹, Yao Yibing¹, Jiang Yanfeng¹, Ma Jie¹

1. Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021,China;
2.Department of Hematology, the People’s Hospital of Beihai, Beihai 536000,China

Received:2015-09-15 Online:2016-01-05 Published:2016-04-19
Contact: Ma Jie,Email:majie086@163.com

摘要/Abstract

摘要： 目的探讨霍奇金淋巴瘤(HL)的临床特点与预后的关系。方法回顾2004年1~12月在我院初治的69例成人HL患者的临床资料,分析各临床特征与预后的关系。结果 ①50例(72.5%)患者以颈部淋巴结肿大起病,病理以混合细胞型最多见。②治疗有效率达76.8％(53/69)。5年总生存率及无失败生存率分别为80.0%和72.0%。③单因素分析显示年龄、分期、结外器官侵犯、脾大、淋巴瘤国际预后指数(International Prognostic Index,IPI)分组、血红蛋白、一线化疗方案、化疗疗程、缓解情况是影响生存的主要因素(P＜0.05)。④多因素分析显示缓解情况是影响HL患者生存的主要因素(P＜0.05)。结论 HL患者以颈部淋巴结肿大起病最常见,治疗后缓解情况是HL独立预后危险因素。

关键词: 淋巴瘤, 霍奇金, 预后, 体征和症状

Abstract: Objective To explore the clinical characteristics and prognosis of Hodgkin lymphoma(HL).Methods The clinical data of 69 adult patients with HL treated at our hospital from Jan. 2004 to Dec. 2014 were analyzed retrospectively,analyzing the clinical characteristics with prognosis.Results ①50 patients (72.5%) had cervical lymph nodes involvement in the pre-treatment evaluation.Pathological study revealed that mixed cellularity was most common.②The response rate was 76.8%(53/69). The rates of 5-years overall survival rate and failure free survival were 80.0% and 72.0%.③Kaplan-Meier single-factor analysis showed that age,clinical staging,extra nodal tissues involvement, splenomegaly,International Prognostic Index(IPI) grouping, hemoglobin, first-line chemotherapy regimens,chemotherapy course, remission were the main factors influencing the survival (P<0.05).④Cox model multivariate analysis indicated that remission was the main factor affecting the survival (P<0.05).Conclusion Cervical lymph node was the most common involvement site with HL. Remission was the independent prognosis risk factor for HL.

Key words: lymphoma,hodgkin, prognosis, signs and symptoms

中图分类号:

R733.41

赵卫华, 徐海萍, 彭志刚, 姚奕斌, 姜彦枫, 马劼. 成人霍奇金淋巴瘤69例临床预后分析[J]. 临床荟萃, 2016, 31(1): 59-62.

Zhao Weihua, Xu Haiping, Peng Zhigang, Yao Yibing, Jiang Yanfeng, Ma Jie. Clinical prognostic analysis on 69 cases of adult Hodgkin lymphoma[J]. Clinical Focus, 2016, 31(1): 59-62.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.01.015

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I1/59

参考文献

[1] 董颖,陈赛娟.淋巴瘤的流行病学[M]//沈志祥,朱雄增.恶性淋巴瘤.2版.北京:人民卫生出版社,2011:25-26.
[2] Jaffe ES, Harris HL, Stein M, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World health organization classification of tumor[M].Lyon:IARC Press, 2001:150-153.
[3] Federico M,Luminari S,Iannitto E,et al.ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma:results from the HD2000 Gruppo Italiato perlo Studio dei Linfomi Trital[J]. J Clin Oncol,2009,27(1):805-811.
[4] Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting[J]. J Clin Oncol,1989,7(11):1630-1666.
[5] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol,2007,25(5):579-586.
[6] 李小秋,李甘地,高子芬,等.中国淋巴瘤亚型分布:国内多中心性病例10002例分析[J].诊断学理论与实践,2012,11(2):111-115.
[7] Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244[J]. J Clin Oncol, 2009, 27(32): 5390-5396.
[8] 谭文勇, 胡德胜, 宋启斌, 等. 早期霍奇金淋巴瘤的预后多因素分析[J]. 肿瘤, 2008, 28(6): 510-513.
[9] Provencio M, Espaa P, Milln I, et al. Prognostic factors in Hodgkin's disease[J]. Leuk Lymphoma, 2004, 45(6): 1133-1139.
[10] Shipp M. Prognostic factors in non-Hodgkin's lymphoma[J]. Curr Opin Oncol,1992, 4(5): 856-862.
[11] 赵春, 张尚福, 李甘地. 143例霍奇金淋巴瘤的WHO分类草案应用及临床病理分析[J]. 临床与实验病理学杂志, 2000, 16(2): 96-99.
[12] Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned[J]. N Engl J Med, 2011, 365(3): 203-212.
[13] 付晓红,陈碧君,马萍,等. 霍奇金淋巴瘤综合治疗的临床分析[J]. 实用癌症杂志, 2014, 29(1): 93-96.
[14] 黄进,钟美佐,舒毅刚,等. 霍奇金淋巴瘤121例临床预后因素分析[J].中国现代医学杂志,2005,15(8):1256-1259.
[15] Tubiana M, Henry M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987[J]. Blood, 1989, 73(1): 47-56.
[16] Carde P, Burgers JM, Henry M, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors[J]. J Clinical Oncol, 1988, 6(2): 239-252.
[17] Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease[J]. N Engl J Med, 1998, 339(21): 1506-1514.
[18] 陶云霞,康愫意,孙剑笠,等. 晚期霍奇金淋巴瘤115例临床疗效总结与预后分析[J].癌症进展,2013,11(3):259-263.
[19] Russo F, Lastoria S, Svanera G, et al. Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma[J]. Leuk Lymphoma,2007, 48(4): 723-730.
[20] Bonnet C, Beguin Y, Fassotte MF, et al. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma[J]. Eur J Haematol, 2007, 78(5): 399-404.

成人霍奇金淋巴瘤69例临床预后分析

Clinical prognostic analysis on 69 cases of adult Hodgkin lymphoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵旭辉, 黄小敏, 达德转, 许焱, 崔晓东, 李红玲. 基于生物信息学筛选影响胃癌患者预后的糖酵解相关基因[J]. 临床荟萃, 2024, 39(1): 20-29.
[2]	刘丽丽, 袁宇婷, 赖耿良, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病第15天微小残留与预后的关系[J]. 临床荟萃, 2024, 39(1): 47-52.
[3]	崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74.
[4]	王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612.
[5]	杨巍, 何晨冬. 以干咳为唯一症状的原发性肺黏膜相关淋巴组织淋巴瘤1例并文献复习[J]. 临床荟萃, 2023, 38(7): 623-627.
[6]	张会, 丁东瑞, 金天然. 新型冠状病毒SARS-CoV-2的相关研究——过去与未来[J]. 临床荟萃, 2023, 38(7): 638-646.
[7]	高秦宇, 包蓓艳, 金燕, 赵宇. IgA肾病合并抑郁状态患者的临床特征和预后影响因素分析[J]. 临床荟萃, 2023, 38(6): 510-515.
[8]	孙星星, 林海. 儿童重症肺炎的免疫功能变化及预后危险因素[J]. 临床荟萃, 2023, 38(6): 521-525.
[9]	贺翔渝, 潘燕, 张小林. 血清脂蛋白相关磷脂酶A2水平与急性缺血性脑卒中病情及预后的关系[J]. 临床荟萃, 2023, 38(4): 315-318.
[10]	杨金强, 张仁敏. 降钙素原与血小板比值评估发热伴血小板减少综合征预后的价值[J]. 临床荟萃, 2023, 38(4): 346-351.
[11]	杜佳宜, 刘丽丽, 何永忠, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病化疗期间严重不良事件临床观察[J]. 临床荟萃, 2023, 38(2): 149-154.
[12]	张娜, 孙越, 董晗, 赵鹏, 杨昕, 祁源, 王玲玲. SPARC表达水平与非小细胞肺癌患者预后关系的meta分析[J]. 临床荟萃, 2023, 38(11): 972-978.
[13]	王会新, 赵芳晴, 张馨妍, 侯晓雯. 中国人尿酸水平与急性缺血性脑卒中患者预后关系的meta分析[J]. 临床荟萃, 2022, 37(9): 785-790.
[14]	邢婷婷, 高俊茶. Presepsin在急性胰腺炎中的研究进展[J]. 临床荟萃, 2022, 37(8): 764-768.
[15]	轩晓倩, 赵君慧, 杨小茜. 炎性指标在非小细胞肺癌患者预后中的临床意义[J]. 临床荟萃, 2022, 37(7): 663-667.